{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:24:01Z","timestamp":1792063441199,"version":"4.4.0"},"reference-count":71,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,4,7]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>Peripheral spondyloarthritis (pSpA) refers to a number of seemingly different spondyloarthritis subsets in which psoriatic arthritis (PsA) is the most common, and symptoms of arthritis, enthesitis or dactylitis predominate the clinical presentation. Although formal classification criteria for pSpA have been introduced in 2011, only a minority of epidemiological and clinical studies addressed this clinical entity as a separate disease. Moreover, research on outcome measures and treatment modalities in pSpA has been mainly focused on PsA. Subsequently, all biological treatments are off-label in patients with non-psoriatic pSpA. Its neglected status has important implications for clinical practice since the emerging group of early-diagnosed non-psoriatic pSpA patients remains poorly characterised and lacks specific treatment recommendations. This review summarises what is currently known regarding pSpA in terms of epidemiology, clinical presentation, diagnosis and therapeutic approach.<\/jats:p>","DOI":"10.1136\/rmdopen-2019-001136","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:01:22Z","timestamp":1588917682000},"page":"e001136","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":74,"title":["Peripheral spondyloarthritis: a neglected entity\u2014state of the art"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-6171","authenticated-orcid":false,"given":"Philippe","family":"Carron","sequence":"first","affiliation":[{"name":"Rheumatology, University Hospital Ghent, Ghent, Belgium"},{"name":"VIB Center for Inflammation Research, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Sophie","family":"De Craemer","sequence":"additional","affiliation":[{"name":"Rheumatology, University Hospital Ghent, Ghent, Belgium"},{"name":"VIB Center for Inflammation Research, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"Rheumatology, University Hospital Ghent, Ghent, Belgium"},{"name":"VIB Center for Inflammation Research, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"2025090312050228000_6.1.e001136.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"2025090312050228000_6.1.e001136.2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197409000-00002"},{"key":"2025090312050228000_6.1.e001136.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2025090312050228000_6.1.e001136.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2025090312050228000_6.1.e001136.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202089"},{"key":"2025090312050228000_6.1.e001136.6","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000802","article-title":"Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis","volume":"5","author":"de Winter","year":"2019","journal-title":"RMD Open"},{"key":"2025090312050228000_6.1.e001136.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.20990"},{"key":"2025090312050228000_6.1.e001136.8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/acr.21621","article-title":"Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey","volume":"64","author":"Reveille","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312050228000_6.1.e001136.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.21609"},{"key":"2025090312050228000_6.1.e001136.10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.semarthrit.2015.09.001","article-title":"Similarities and differences between patients fulfilling axial and peripheral ASAS criteria for spondyloarthritis: results from the Esperanza Cohort","volume":"45","author":"Del Rio-Martinez","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312050228000_6.1.e001136.11","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/art.39628","article-title":"Two phenotypes are identified by cluster analysis in early inflammatory back pain suggestive of spondyloarthritis: results from the DESIR Cohort","volume":"68","author":"Costantino","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025090312050228000_6.1.e001136.12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312050228000_6.1.e001136.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210775"},{"key":"2025090312050228000_6.1.e001136.14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.semarthrit.2018.02.002","article-title":"Dactylitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312050228000_6.1.e001136.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171094"},{"key":"2025090312050228000_6.1.e001136.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009092","article-title":"Analysis of HLA-B15 and HLA-B27 in spondyloarthritis with peripheral and axial clinical patterns","volume":"11","author":"Londono","year":"2015","journal-title":"BMJ Open"},{"key":"2025090312050228000_6.1.e001136.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.10.010"},{"key":"2025090312050228000_6.1.e001136.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"2025090312050228000_6.1.e001136.19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"2025090312050228000_6.1.e001136.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171411"},{"key":"2025090312050228000_6.1.e001136.21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.rdc.2016.07.012","article-title":"Imaging evaluation of the entheses: ultrasonography, MRI, and scoring of evaluation","volume":"42","author":"D\u2019Agostino","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090312050228000_6.1.e001136.22","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/annrheumdis-2018-213609","article-title":"Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative","volume":"77","author":"Balint","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312050228000_6.1.e001136.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070243"},{"key":"2025090312050228000_6.1.e001136.24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/1744666X.2016.1215245","article-title":"Psoriatic arthritis: lessons from imaging studies and implications for therapy","volume":"13","author":"Mathew","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090312050228000_6.1.e001136.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.20566"},{"key":"2025090312050228000_6.1.e001136.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181093"},{"key":"2025090312050228000_6.1.e001136.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341003"},{"key":"2025090312050228000_6.1.e001136.28","first-page":"85","article-title":"[Criteria of the classification of spondylarthropathies]","volume":"57","author":"Amor","year":"1990","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"2025090312050228000_6.1.e001136.29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1297-319X(00)00201-3","article-title":"Can some cases of \u2018possible\u2019 spondyloarthropathy be classified as \u2018definite\u2019 or \u2018undifferentiated\u2019 spondyloarthropathy? Value of criteria for spondyloarthropathies. Spanish Spondyloarthropathy Study Group","volume":"67","author":"Collantes","year":"2000","journal-title":"Joint, Bone, Spine: Revue Du Rhumatisme"},{"key":"2025090312050228000_6.1.e001136.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090312050228000_6.1.e001136.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025090312050228000_6.1.e001136.32","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025090312050228000_6.1.e001136.33","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025090312050228000_6.1.e001136.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207235"},{"key":"2025090312050228000_6.1.e001136.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202245"},{"key":"2025090312050228000_6.1.e001136.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121533"},{"key":"2025090312050228000_6.1.e001136.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030783"},{"key":"2025090312050228000_6.1.e001136.38","first-page":"S17","article-title":"The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide","volume":"19","author":"Sarzi-Puttini","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312050228000_6.1.e001136.39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/annrheumdis-2018-eular.5331","article-title":"Peripheral manifestations in spondyloarthritis: impact on patient-reported outcomes (pros) and treatment. Data from asas-comospa","volume":"77","author":"Lopez-Medina","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312050228000_6.1.e001136.40","doi-asserted-by":"publisher","DOI":"10.1002\/art.22467"},{"key":"2025090312050228000_6.1.e001136.41","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00296-016-3440-4","article-title":"Ultrasound-guided retro-calcaneal bursa corticosteroid injection for refractory Achilles tendinitis in patients with seronegative spondyloarthropathy: efficacy and follow-up study","volume":"36","author":"Srivastava","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025090312050228000_6.1.e001136.42","doi-asserted-by":"publisher","DOI":"10.1002\/art.20253"},{"key":"2025090312050228000_6.1.e001136.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380507"},{"key":"2025090312050228000_6.1.e001136.44","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C"},{"key":"2025090312050228000_6.1.e001136.45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes001"},{"key":"2025090312050228000_6.1.e001136.46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152223"},{"key":"2025090312050228000_6.1.e001136.47","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase iii trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025090312050228000_6.1.e001136.48","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140879"},{"key":"2025090312050228000_6.1.e001136.49","doi-asserted-by":"publisher","DOI":"10.1002\/art.511"},{"key":"2025090312050228000_6.1.e001136.50","doi-asserted-by":"publisher","DOI":"10.1002\/art.21426"},{"key":"2025090312050228000_6.1.e001136.51","first-page":"531","article-title":"Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept","volume":"31","author":"Brandt","year":"2004","journal-title":"J Rheumatol"},{"key":"2025090312050228000_6.1.e001136.52","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H"},{"key":"2025090312050228000_6.1.e001136.53","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.74"},{"key":"2025090312050228000_6.1.e001136.54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203327"},{"key":"2025090312050228000_6.1.e001136.55","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/art.40573","article-title":"High rate of drug-free remission after induction therapy with golimumab in early peripheral spondyloarthritis","volume":"70","author":"Carron","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025090312050228000_6.1.e001136.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.05.011"},{"key":"2025090312050228000_6.1.e001136.57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"2025090312050228000_6.1.e001136.58","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"2025090312050228000_6.1.e001136.59","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet (London, England)"},{"key":"2025090312050228000_6.1.e001136.60","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2025090312050228000_6.1.e001136.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2025090312050228000_6.1.e001136.62","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000567","article-title":"Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naive patients with active psoriatic arthritis (PsA): results from SPIRIT-P1","volume":"3","author":"Coates","year":"2017","journal-title":"RMD Open"},{"key":"2025090312050228000_6.1.e001136.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"2025090312050228000_6.1.e001136.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090312050228000_6.1.e001136.65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"2025090312050228000_6.1.e001136.66","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"2025090312050228000_6.1.e001136.67","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"2025090312050228000_6.1.e001136.68","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet (London, England)"},{"key":"2025090312050228000_6.1.e001136.69","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171406"},{"key":"2025090312050228000_6.1.e001136.70","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32833ac5cc"},{"key":"2025090312050228000_6.1.e001136.71","first-page":"1","article-title":"Diagnostic efficacy of ultrasound detection of enthesitis in peripheral spondyloarthritis","volume":"14","author":"Fujikawa","year":"2019","journal-title":"Mod Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:05:10Z","timestamp":1756926310000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,7]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/rmdopen-2019-001136"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001136","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}